Technical Analysis for CKPT - Checkpoint Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Outside Day | Range Expansion | 0.00% | |
| NR7 | Range Contraction | -0.49% | |
| NR7-2 | Range Contraction | -0.49% | |
| Gapped Down | Weakness | -0.49% | |
| 20 DMA Support | Bullish | -0.97% | |
| 200 DMA Support | Bullish | -0.97% | |
| MACD Bullish Signal Line Cross | Bullish | -0.97% | |
| NR7 | Range Contraction | -0.97% | |
| Gapped Down | Weakness | -0.97% | |
| Gapped Up | Strength | -1.91% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 4 hours ago |
| 60 Minute Opening Range Breakdown | about 4 hours ago |
| Outside Day | about 4 hours ago |
| Down 5% | about 4 hours ago |
| Fell Below Previous Day's Low | about 4 hours ago |
Get a Trading Assistant
- Earnings date: 08/12/2024
Checkpoint Therapeutics, Inc. Description
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Antibodies Cancer Immunotherapy Chemotherapy Epidermal Growth Factor Receptor Immune Checkpoint Solid Tumor Cancers Checkpoint Inhibitor Necrosis Tumor Necrosis Factor Immuno Oncology Biopharmaceutical Tumor Necrosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.62 |
| 52 Week Low | 1.3 |
| Average Volume | 371,490 |
| 200-Day Moving Average | 1.97 |
| 50-Day Moving Average | 1.78 |
| 20-Day Moving Average | 1.98 |
| 10-Day Moving Average | 2.02 |
| Average True Range | 0.15 |
| RSI (14) | 55.95 |
| ADX | 28.92 |
| +DI | 19.59 |
| -DI | 12.95 |
| Chandelier Exit (Long, 3 ATRs) | 1.75 |
| Chandelier Exit (Short, 3 ATRs) | 2.25 |
| Upper Bollinger Bands | 2.18 |
| Lower Bollinger Band | 1.79 |
| Percent B (%b) | 0.67 |
| BandWidth | 19.85 |
| MACD Line | 0.07 |
| MACD Signal Line | 0.07 |
| MACD Histogram | 0.0032 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.29 | ||||
| Resistance 3 (R3) | 2.30 | 2.23 | 2.25 | ||
| Resistance 2 (R2) | 2.23 | 2.17 | 2.23 | 2.24 | |
| Resistance 1 (R1) | 2.14 | 2.13 | 2.11 | 2.13 | 2.22 |
| Pivot Point | 2.07 | 2.07 | 2.05 | 2.07 | 2.07 |
| Support 1 (S1) | 1.98 | 2.01 | 1.95 | 1.97 | 1.88 |
| Support 2 (S2) | 1.91 | 1.97 | 1.91 | 1.86 | |
| Support 3 (S3) | 1.82 | 1.91 | 1.85 | ||
| Support 4 (S4) | 1.81 |
